GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. (GEHC) Market Cap

GE HealthCare Technologies Inc. has a market capitalization of $34.07B.

Financials based on reported quarter end 2025-12-31

Price: $74.66

1.46 (1.99%)

Market Cap: 34.07B

NASDAQ · time unavailable

CEO: Peter J. Arduini

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2022-12-15

Website: https://www.gehealthcare.com

GE HealthCare Technologies Inc. (GEHC) - Company Information

Market Cap: 34.07B · Sector: Healthcare

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Analyst Sentiment

74%
Strong Buy

Based on 20 ratings

Analyst 1Y Forecast: $88.89

Average target (based on 3 sources)

Consensus Price Target

Low

$77

Median

$90

High

$105

Average

$91

Potential Upside: 21.9%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 GE HealthCare Technologies Inc. (GEHC) — Investment Overview

🧩 Business Model Overview

GE HealthCare Technologies Inc. (GEHC) operates as a global medical technology and digital solutions provider, serving hospitals, clinics, and healthcare systems worldwide. The company’s offerings span diagnostic imaging, ultrasound, patient monitoring, and a suite of digital and artificial intelligence-enabled services. GEHC’s diversified product portfolio addresses the full continuum of care—ranging from acute care settings to outpatient clinics. Customers include large integrated health systems, independent care providers, academic centers, and research institutions. Through its broad operating presence, GEHC maintains active engagement in key healthcare domains, supporting both established markets and emerging regions with scalable solutions.

💰 Revenue Model & Ecosystem

GEHC derives revenue from a multi-stream approach that blends equipment sales, recurring consumables and disposables, subscription-based software solutions, and value-added service contracts. Hardware such as imaging systems and monitoring devices forms a foundational revenue pillar, often coupled with ongoing maintenance, upgrades, and technical support. The digital transformation in healthcare has enabled the expansion of software and data analytics platforms, further embedding GEHC’s offerings into customer workflows. This mix provides a blend of upfront and predictable, recurring revenue sources, with enterprise clients forming a dominant share, complemented by smaller clinical or ambulatory care settings.

🧠 Competitive Advantages

  • Brand strength: GEHC leverages the heritage and global recognition of the GE brand, which is widely associated with innovation, reliability, and trust in healthcare technology.
  • Switching costs: High integration of systems, technical complexity, and staff training needs create significant barriers for customers to switch suppliers.
  • Ecosystem stickiness: Interconnected devices, digital platforms, and service networks foster long-term relationships and deepen integration into hospital operations.
  • Scale + supply chain leverage: The company’s extensive manufacturing footprint, procurement power, and global service infrastructure enable operational efficiencies and cost advantages over smaller competitors.

🚀 Growth Drivers Ahead

Key growth catalysts for GEHC include the global expansion of access to advanced diagnostic technologies, increasing public and private healthcare investment, and rising demand for digital health solutions. The modernization of healthcare infrastructure—especially in emerging markets—supports the adoption of higher-value imaging and monitoring platforms. Strategic focus on cloud-enabled software, predictive analytics, and artificial intelligence paves the way for enhanced clinical outcomes and broader digital transformation. Moreover, service and lifecycle management solutions offer attractive avenues for recurring revenue while deepening customer entrenchment. Acquisitions and partnerships with leading healthcare providers help fuel geographic and technological expansion.

⚠ Risk Factors to Monitor

GEHC faces risks from intense competition among diversified healthcare technology companies, as well as from nimble new entrants, which can exert pressure on pricing and innovation. Regulatory compliance remains a persistent challenge in the industry, with evolving standards across global markets potentially impacting product rollout and cost structures. Margin pressures can arise from reimbursement changes, supply chain volatility, and macroeconomic headwinds. Technological disruption—including rapid shifts toward new modalities or software-centric care models—requires sustained investment and adaptability to maintain leadership.

📊 Valuation Perspective

The market generally assigns GEHC a valuation reflective of its entrenched competitive position, global scale, and consistent cash generation. Compared to smaller pure-play medical device or digital health firms, GEHC may command a premium for breadth and stability, or trade in line with established diversified peers. Market perceptions often hinge upon the company’s ability to deliver innovation, execute digital transformation, and sustain profitable growth within a dynamic healthcare environment.

🔍 Investment Takeaway

For investors, GE HealthCare Technologies represents a blend of core healthcare infrastructure exposure and emerging digital health potential. The bull case is anchored in robust barriers to entry, an expanding market for high-end diagnostics and data-driven services, and operational leverage from global scale. The bear case revolves around competitive pressures, regulatory unpredictability, and the challenge of pivoting swiftly as the sector embraces rapid technological change. Ultimately, GEHC offers a compelling position within the evolving healthcare landscape, with risk/reward dynamics shaped by its execution in innovation, customer retention, and market expansion.


⚠ AI-generated research summary — not financial advice. Validate using official filings & independent analysis.

GE HealthCare delivered a solid Q4 with broad-based organic growth, a record backlog, and strong cash generation, though tariffs and mix compressed margins. Management highlighted robust demand in the U.S. and EMEA, accelerating innovation, and enterprise deal momentum. 2026 guidance calls for modest organic growth with margin and EPS expansion and improving free cash flow, while remaining cautious on China and acknowledging near-term tariff headwinds. Overall tone was confident on execution and pipeline, balanced by external pressures.

Growth

  • Q4 revenue $5.7B; organic growth +4.8% YoY; product +7.9% (reported), service +5.5% (reported)
  • Q4 orders +2% YoY; book-to-bill 1.06x; record backlog $21.8B (+$2B YoY, +$600M seq)
  • FY2025 revenue $20.6B; organic growth +3.5% (ahead of guidance); organic orders mid-single digits; service grew mid-single digits
  • Q4 segment organic growth: Imaging +5.3%; Advanced Visualization Solutions +4.2%; Pharmaceutical Diagnostics +12.7%; Patient Care Solutions -1.1%
  • Three-year vitality rate: 55% of revenue from new products

Business Development

  • Enterprise deals >$7B since spin; multiple large agreements secured/extended in Q4
  • 7-year collaboration with University of Rochester Medical Center across imaging, radiopharma, monitoring, and services
  • Large collaboration with Sutter Health; multiyear agreement with Indonesia Ministry of Health (300+ CT installations)
  • 20-year collaboration with Nuffield Health (UK)
  • Planned acquisition of IntelliRed (cloud-first imaging SaaS); first full-year revenue ≈$270M, low double-digit growth, >30% adjusted EBITDA
  • Ongoing tuck-in M&A (e.g., Neon Metaphysics, Eichometrics); seven acquisitions closed since spin

Financials

  • Q4 adjusted EBIT margin 16.7% (-200 bps YoY) with ≈$100M tariff headwind; adjusted EPS $1.44 (-0.7% YoY), ~$0.17 tariff impact; EPS +11% ex-tariffs
  • Q4 free cash flow $916M (+$105M YoY), including ≈$90M tariff impact
  • FY2025 adjusted EBIT margin 15.3% (-100 bps YoY); adjusted EPS $4.59 (+2.2% YoY); tariffs impacted EBIT by ≈$245M and EPS by $0.43
  • Excluding tariffs, FY2025 adjusted EBIT margin +20 bps and adjusted EPS +12%
  • FY2025 free cash flow $1.5B (72% conversion), including ≈$285M tariff impact

Capital & Funding

  • Invested >$1.7B in innovation in 2025
  • Deleveraged balance sheet; maintained investment-grade ratings
  • Returned capital via dividend and $200M share repurchases since April authorization (avg price ~$71)
  • Continued inorganic investment (tuck-ins; planned IntelliRed acquisition)
  • 2026 free cash flow outlook ≈$1.7B (+13% YoY)

Operations & Strategy

  • Heartbeat business system (SQDCI) driving lean execution; average monthly past-due backlog improved 25% vs prior year
  • Tariff mitigation via supply-chain shifts: moved PET/CT and surgery lines to the U.S.; partnered with contract manufacturers to reposition production; expanding USMCA duty-free efforts
  • Precision care D3 strategy integrating devices, drugs, and digital/AI/cloud
  • Advancing NPIs: photon-counting CT, new MR platform, Omni Total Body PET, NexGen SPECT; strong uptake of VividPioneer cardiovascular ultrasound
  • Service capture expected to rise with new installed base; monitoring transformation on track

Market & Outlook

  • Capital equipment environment healthy; demand strong in U.S. and EMEA; more large U.S. customers plan 2026 capex
  • ASNC recommends PET over SPECT, supporting PET shift in nuclear cardiology
  • 2026 guidance: organic revenue +3–4% (FX tailwind ≈150 bps); adjusted EBIT margin 15.8–16.1% (+50–80 bps); adjusted EPS $4.95–$5.15 (+8–12%); FCF ≈$1.7B
  • Q1 2026: organic revenue +2–3%; largest tariff impact of the year expected, but mid-single-digit adjusted EPS growth
  • Cautious outlook on China; robust NPI pipeline expected to support orders beginning in 2026

Risks Or Headwinds

  • Tariffs materially pressured 2025 results; still elevated in early 2026 despite mitigation actions
  • Unfavorable mix and inflation impacted margins
  • Cautious demand outlook in China
  • Patient Care Solutions faced life support solutions decline and prior product hold (shipments restored)
  • Execution risks around regulatory approvals and manufacturing ramp for new radiopharmaceuticals; continued focus on site readiness/backlog conversion

Sentiment: MIXED

Note: This summary was synthesized by AI from the GEHC Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"General Electric HealthCare (GEHC) reported revenues of $4.67 billion for Q4 2025, with a net income of $184 million translating to an EPS of $0.41. The gross net margin stands at approximately 3.9%. Free cash flow was significantly negative at -$454 million. Compared year-over-year, the market performance has declined by around 12%, aligning with a challenging operational landscape. Revenue growth for GEHC is moderate, supported primarily by core segment expansion, though current macroeconomic conditions pose headwinds. The operating margin remains thin, reflecting a highly competitive environment and cost pressures. Negative cash flow is concerning, driven by operational disruptions, with signs of distress from the substantial free cash flow deficit. Leverage is managed carefully, given the net debt position is favorable at -$4 billion, indicating a surplus of cash over debt. The balance sheet remains robust with a total equity of $10.39 billion against the backdrop of substantial total assets. Shareholder returns, though impacted by the recent downturn, continue to be upheld through sequential quarterly dividends and stock buybacks amounting to $200 million. Analyst sentiment per price targets suggests potential for moderate recovery with a consensus target of $89.8, despite the current market volatility."

Revenue Growth

Neutral

Revenue growth is steady but faces temporary macroeconomic pressures. Expansion prospects are primarily driven by existing product lines.

Profitability

Caution

Profit margins are thin at 3.9%, reflecting competitive pressures and operational inefficiencies affecting bottom-line growth.

Cash Flow Quality

Neutral

Negative free cash flow is a significant concern, driven by operational challenges. Liquidity is adequate, but cash generation is weak.

Leverage & Balance Sheet

Positive

Strong net cash position with net debt at -$4 billion, indicating financial resilience despite operational cash flow issues.

Shareholder Returns

Neutral

Despite earnings headwinds, dividends are stable, supplemented by significant buybacks, demonstrating a commitment to returning value to shareholders.

Analyst Sentiment & Valuation

Fair

Current valuations align with broader market trends; however, there is cautious optimism shown by price targets predicting potential upside.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
📁

SEC Filings (GEHC)

© 2026 Stock Market Info — GE HealthCare Technologies Inc. (GEHC) Financial Profile